DeCherney A H, diZerega G S
Livingston Reproductive Biology Laboratory, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, USA.
Surg Clin North Am. 1997 Jun;77(3):671-88. doi: 10.1016/s0039-6109(05)70574-0.
Because of multiple studies demonstrating barrier efficacy, adhesion prevention adjuvants have received widespread acceptance in appropriate surgical settings. Many investigators are incorporating adhesion prevention barriers into their routine clinical practice and are achieving good results. Although both Seprafilm and Interceed barriers were shown to be safe and effective in all human clinical trials, their use did not eliminate adhesions in all patients. Efficacy of these barriers is limited to surgical situations in which the area in question can be completely covered. Physician acceptance is constrained by technical difficulties, including the need for hemostasis and removal of excess peritoneal fluid (Interceed), as well as limitations in application and handling properties within the surgical field (Seprafilm).
